Rituximab treatment circumvents the ...
Type de document :
Article dans une revue scientifique
PMID :
URL permanente :
Titre :
Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients
Auteur(s) :
Xerri, Luc [Auteur]
Huet, Sarah [Auteur]
Venstrom Jeffrey, M [Auteur]
Szafer-Glusman, Edith [Auteur]
Fabiani, Bettina [Auteur]
Canioni, Danielle [Auteur]
Chassagne-Clement, Catherine [Auteur]
Dartigues-Cuilleres, Peggy [Auteur]
Charlotte, Frederic [Auteur]
Laurent, Camille [Auteur]
Gelas-Dore, Benedicte [Auteur]
Bolen Christopher, R [Auteur]
Punnoose, Elizabeth [Auteur]
Bouabdallah, Reda [Auteur]
Brice, Pauline [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Cartron, Guillaume [Auteur]
Olive, Daniel [Auteur]
Salles, Gilles [Auteur]
Huet, Sarah [Auteur]
Venstrom Jeffrey, M [Auteur]
Szafer-Glusman, Edith [Auteur]
Fabiani, Bettina [Auteur]
Canioni, Danielle [Auteur]
Chassagne-Clement, Catherine [Auteur]
Dartigues-Cuilleres, Peggy [Auteur]
Charlotte, Frederic [Auteur]
Laurent, Camille [Auteur]
Gelas-Dore, Benedicte [Auteur]
Bolen Christopher, R [Auteur]
Punnoose, Elizabeth [Auteur]
Bouabdallah, Reda [Auteur]
Brice, Pauline [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Cartron, Guillaume [Auteur]
Olive, Daniel [Auteur]
Salles, Gilles [Auteur]
Titre de la revue :
Human pathology
Nom court de la revue :
Hum. Pathol.
Numéro :
64
Pagination :
128-136
Date de publication :
2017
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Previous immunohistochemical (IHC) studies showed controversial data about the prognostic value of tumor-infiltrating lymphocytes (TILs) in follicular lymphoma (FL). To clarify this issue, a large series of FL samples ...
Lire la suite >Previous immunohistochemical (IHC) studies showed controversial data about the prognostic value of tumor-infiltrating lymphocytes (TILs) in follicular lymphoma (FL). To clarify this issue, a large series of FL samples from rituximab-treated patients enrolled in the randomized PRIMA trial was examined. IHC was quantified using automated image analysis in 417, 287, 418, 406, 379, and 369 patients for CD3, CD4, CD8, PD1, ICOS, and FOXP3, respectively. RNAseq analysis was used to quantify TIL-related mRNA transcripts from 148 patients. When each IHC marker was used as a continuous variable in the whole cohort, high CD3 counts were associated with better progression-free survival (PFS) (P = .025). When an optimal IHC cut point was applied to the whole patient population, high CD3 counts and high PD1 counts were associated with better PFS (P = .011 and P = .044, respectively), whereas none of the other TIL markers had any significant correlation with outcome. When a stringent analysis was performed by dividing the whole cohort into a training set and a validation set, none of the TIL markers showed a prognostic significance in both groups. RNAseq analysis showed a significant correlation between high levels of CD3 and CD8 transcripts and better PFS (P = .001 and P = .037, respectively). No prognostic correlation was found as to the level of other immune gene transcripts. These results suggest that the IHC prognostic value of TILs is circumvented by rituximab treatment, although there is a trend for high numbers of CD3+ TILs to correlate with better PFS.Lire moins >
Lire la suite >Previous immunohistochemical (IHC) studies showed controversial data about the prognostic value of tumor-infiltrating lymphocytes (TILs) in follicular lymphoma (FL). To clarify this issue, a large series of FL samples from rituximab-treated patients enrolled in the randomized PRIMA trial was examined. IHC was quantified using automated image analysis in 417, 287, 418, 406, 379, and 369 patients for CD3, CD4, CD8, PD1, ICOS, and FOXP3, respectively. RNAseq analysis was used to quantify TIL-related mRNA transcripts from 148 patients. When each IHC marker was used as a continuous variable in the whole cohort, high CD3 counts were associated with better progression-free survival (PFS) (P = .025). When an optimal IHC cut point was applied to the whole patient population, high CD3 counts and high PD1 counts were associated with better PFS (P = .011 and P = .044, respectively), whereas none of the other TIL markers had any significant correlation with outcome. When a stringent analysis was performed by dividing the whole cohort into a training set and a validation set, none of the TIL markers showed a prognostic significance in both groups. RNAseq analysis showed a significant correlation between high levels of CD3 and CD8 transcripts and better PFS (P = .001 and P = .037, respectively). No prognostic correlation was found as to the level of other immune gene transcripts. These results suggest that the IHC prognostic value of TILs is circumvented by rituximab treatment, although there is a trend for high numbers of CD3+ TILs to correlate with better PFS.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Équipe(s) de recherche :
Innovation/évaluation des médicaments injectables
Date de dépôt :
2019-02-26T17:07:11Z